- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00833807
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Study Drug:
Nab-paclitaxel is designed to block cancer cells from dividing, which may cause them to die.
Study Drug Groups:
If you are found to be eligible to take part in this study, you will be assigned to a dose level of nab-paclitaxel based on when you joined this study. Up to 4 dose levels of nab-paclitaxel will be tested. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of nab-paclitaxel is found.
Study Drug Administration:
During Cycles 1-6, you will admitted to the hospital the day before each time you are scheduled to receive the study drug. On the day after you are admitted (Day 1), you will have a catheter inserted into the hepatic artery (the major blood vessel that carries blood to the liver). You will be separately consented for this procedure, which will describe the procedure and its risks in detail. If the melanoma has spread to your skin, you may also be asked to take part in a separate laboratory study. In that study, you will have a tumor biopsy to check the concentration of a protein called SPARC in the tumor. Earlier clinical trials have shown that patients with tumors containing high levels of SPARC have better chance of the tumor shrinking with nab-paclitaxel treatment. You do not have to agree to the laboratory study in order to take part in this main study.
On Day 1 of Cycles 1-6, you will then receive nab-paclitaxel through the arterial catheter over 30 minutes. The catheter will be removed after you receive the study drug.
Your vital signs will be measured before and after you receive the study drug. You will be sent home from the hospital the next day if your vital signs are stable.
On Day 1 of Cycle 7 and beyond, you will receive the study drug through a catheter in your vein over 30 minutes. You will not need to stay in the hospital when you receive the study drug by vein.
On Day 1 of all cycles, before you receive the study drug, you will receive drugs to help to prevent for nausea and vomiting.
Each cycle is 3 weeks.
Study Visits:
On Days 1 and 21 (+ or - 4 days) of every cycle, the following tests and procedures will be performed:
- You will have a physical exam, including measurement of your weight.
- Your medical history will be recorded.
- You will be asked if you have experienced any side effects.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a performance status evaluation.
On Days 8 and 15 all cycles, blood (about 1 tablespoon) will be drawn for routine tests.
Before each cycle of therapy, you will have a physical exam. Blood (about 2 tablespoons) will be drawn for routine tests.
Before every other cycle beginning with Cycle 3 (Cycles 3, 5, 7 and so on), you will have CT scans to check the status of the disease.
Length of Study:
You may continue to receive the study drug for as long as you are benefitting. You will be taken off study early if you experience intolerable side effects or the disease gets worse.
End-of-Study Visit:
Within 28 days after the last dose of study drug, you will have an end-of-study visit. The following tests and procedures performed:
- You will have a physical exam.
- You will be asked if you have experienced any side effects.
- You will have a chest x-ray, CT scans, and an ECG to check the status of the disease.
- Blood (about 1 tablespoon) and urine will be collected for routine tests.
- You will be asked about any new symptoms that you may have experienced after you stopped receiving the study drug.
- If the doctor thinks it is necessary, you will have an MRI to check the status of the disease.
This is an investigational study. Nab-paclitaxel is FDA approved and commercially available for the treatment of breast cancer when given by vein. Its use in liver cancer patients, as well as its administration into the hepatic artery, is investigational.
Up to 40 patients will take part in this study. All will be enrolled at M. D. Anderson.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologic confirmation of malignant melanoma, and documented metastatic disease.
- Patients must have at least one clearly measurable metastatic lesion in the liver that is more than 2cm in the largest dimension. Indicator lesions at least 2cm are chosen primarily to have changes in tumor measurement more accurately reflective of effect of therapy, or lack of it.
- Patients must not have received prior systemic chemotherapy with regimens including taxanes. Prior adjuvant treatment with immunotherapy or vaccine therapy is allowed provided there is documentation of disease progression in the liver.
- At least 4 weeks (28 days) since any prior immunotherapy, cytokine, biologic, vaccine therapy or tumor embolization in the liver and patients should have progressed during therapy. Patient must have recovered from any side effects before starting therapy on this protocol.
- At least 4 weeks (28 days) since prior radiotherapy (if radiation therapy field covering > 20% of the bone marrow containing skeletal structures) and prior adjuvant therapy. Patient must have recovered from any side effects before starting therapy on this protocol.
- Lesions being used to assess disease status may not have been radiated or if so, must have progressed during or after radiation therapy.
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.
- Patients must be >/= 18 years of age. The safety of NAB-Paclitaxel has not been studied in younger patients.
- Patients must have normal serum total bilirubin level, transaminase levels (i.e., ALT and AST) no higher than 2.5 times the institution's upper normal limits. Patients must have adequate renal function: creatinine </= 1.5 mg/dL Patients must have adequate bone marrow function as defined by an absolute neutrophil count >/= 1,500/mm^3, platelet count >/= 100,000/mm^3 and hemoglobin >/= 9.0g/dL.
- Life expectancy of at least 3 months.
- Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution.
Exclusion Criteria:
- Patients who have received prior systemic chemotherapy with regimens including taxanes.
- Patients with history of central nervous system (CNS) metastasis prior to registering to this study.
- Patients who are pregnant or nursing and patients who are not practicing an acceptable method of birth control. A negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential. Patients may not breast-feed while on this study.
- Patients with current active infections requiring anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals).
- Patients with current peripheral neuropathy of any etiology that is greater than grade one.
- Patients with unstable or serious concurrent medical conditions are excluded. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
- Patients must not have had major surgery including node dissection, resection of melanoma metastatic to an organ or other surgical procedures that require hospitalization and administration of general anesthesia within the past 14 days.
- Patients must not receive any concurrent chemotherapy, radiotherapy, or immunotherapy while on study.
- Known HIV disease or infection.
- Patients with ascites are not eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nab-paclitaxel (Abraxane)
Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days. Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days. |
Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days. Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Nab-Paclitaxel
Time Frame: 6 weeks
|
The MTD of nab-paclitaxel in participants with metastatic melanoma, previously untreated with systemic chemotherapy, defined as the dose level prior to that resulting in dose limiting toxicity (DLT) (ie., the highest dose level of nab-paclitaxel at which 0 out of 3 patients or 1 out of 6 patients experience DLT).
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival Rate
Time Frame: After 3, 21 day cycles
|
Overall survival (OS) defined as time from first date of study treatment until date of subject death from any cause.
For subjects who have not died, survival data censored at subjects' last known alive date.
Kaplan-Meier method used to estimate distribution and median OS for subjects treated at the MTD level.
Progression-free survival (PFS) defined as time from first date of study treatment to documented disease progression, or to death from any cause within 30 days of last dose of study treatment, whichever occurs earlier.
Disease response including indicator lesions in the liver assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST).
|
After 3, 21 day cycles
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Agop Y. Bedikian, MD, BS, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplastic Processes
- Neuroendocrine Tumors
- Nevi and Melanomas
- Neoplasm Metastasis
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- 2006-0603
- NCI-2010-01023 (Registry Identifier: NCI CTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on Nab-Paclitaxel (Abraxane)
-
M.D. Anderson Cancer CenterNational Comprehensive Cancer NetworkCompletedSolid Tumors | Liver Cancer | Advanced CancersUnited States
-
CelgeneCompletedColorectal NeoplasmsFrance
-
Jilin UniversityNot yet recruitingBreast Cancer StageChina
-
Spanish Breast Cancer Research GroupCelgeneCompleted
-
UNC Lineberger Comprehensive Cancer CenterCelgeneCompletedNon Small Cell Lung Cancer (NSCLC)United States
-
Icahn School of Medicine at Mount SinaiCelgene CorporationTerminated
-
Hellenic Oncology Research GroupCompletedStomach and Gastro-Esophageal Junction (GEJ) CancerGreece
-
Osaka Medical CollegeCompletedBreast Cancer | Effects of Chemotherapy | HER-2 Positive Breast CancerJapan
-
Fondazione Sandro PitiglianiCompleted
-
ETOP IBCSG Partners FoundationBreast International GroupCompletedMetastatic BreastcancerSpain, Ireland, Italy, Switzerland, Slovenia, Belgium